Trade-Ideas LLC identified Inogen ( INGN) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Inogen as such a stock due to the following factors:
INGN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $6.7 million.
INGN has traded 405,331 shares today.
INGN is trading at 18.77 times the normal volume for the stock at this time of day.
INGN is trading at a new high 18.14% above yesterday’s close.
‘Strong on High Relative Volume’ stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from ‘superinvestors,’ or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.
More details on INGN:
Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. INGN has a PE ratio of 76. Currently there are 5 analysts that rate Inogen a buy, no analysts rate it a sell, and none rate it a hold.
The average volume for Inogen has been 169,900 shares per day over the past 30 days. Inogen has a market cap of $673.7 million and is part of the health care sector and health services industry. Shares are down 11.8% year-to-date as of the close of trading on Monday.
EXCLUSIVE OFFER: See inside Jim Cramer’s multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
TheStreet Quant Ratings rates Inogen as a hold. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, premium valuation and a decline in the stock price during the past year.
Highlights from the ratings report include:
INGN’s revenue growth has slightly outpaced the industry average of 30.2%. Since the same quarter one year prior, revenues rose by 38.7%. This growth in revenue appears to have trickled down to the company’s bottom line, improving the earnings per share.
INGN’s debt-to-equity ratio is very low at 0.00 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Along with this, the company maintains a quick ratio of 4.25, which clearly demonstrates the ability to cover short-term cash needs.
INOGEN INC has improved earnings per share by 18.2% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, INOGEN INC reported lower earnings of $0.34 versus $1.22 in the prior year. This year, the market expects an improvement in earnings ($0.45 versus $0.34).
Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. When compared to other companies in the Health Care Equipment & Supplies industry and the overall market, INOGEN INC’s return on equity is below that of both the industry average and the S&P 500.
Source: The Street